Alumis Q2 2026: ONWARD3 shows 54% PASI 100; NDA on track for Q4

ALUMIS INC.

ONWARD3: 75% PASI 90, 54% PASI 100 at 48 weeks (n=773) for envudeucitinib in PsO.
NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis on track for Q4 2026.
Phase 2b LUMUS topline data in SLE expected Q3 2026; prioritizing Sjögren's and CLE.
Q2 net loss $142.2M vs net income $59.3M (incl. $187.9M ACELYRIN gain); $41.8M lonigutamab impairment.
Cash $502.3M; guidance funds into Q4 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.